Replies to post #86756 on China Growth Stocks

[2morrowsGains]

BOPH...One more thing re: BOPH's recent acquisition..."The company's Fangfengtongsheng Granule, which accounted for 59% of sales in 2010, is a prescription product on China's Essential Drug List and qualifies for reimbursement under China's national health insurance system. Fangfengtongsheng Granule is used to treat fever, headache, constipation, measles and eczema. Zhengxintai Capsule, which accounted for 33% of sales in 2010, is a prescription product on China's National Drug Reimbursement List (NDRL) and also qualifies for reimbursement under China's national health insurance system. Zhengxintai Capsule is used to improve kidney function and treat coronary artery disease and angina."
http://ih.advfn.com/p.php?pid=nmona&article=48774632

Acquired company's website...
http://translate.googleusercontent.com/translate_c?hl=en&ie=UTF8&prev=_t&rurl=translate.google.com&sl=zh-CN&tl=en&u=http://www.sdtzyy.com/index0.asp&usg=ALkJrhi6j4Y_aq7B0Dxwa8zizgVa_c8Z8g

I can see NICE growth coming as Bohai integrates products from the acquisition into their product line. Also, vice versa.